Wednesday, 18 Oct 2017

You are here

IL-6 Inhibitor Kevzara Granted FDA Approval for Rheumatoid Arthritis

The FDA has approved sarilumab (Kevzara), a new IL-6 inhibitor co-developed by Regeneron and Sanofi's, for use in adults with moderate to severe rheumatoid arthritis (RA).

Although approved in Canada in February 2017, the US submission of the sarilumabs BLA was held up by the FDA with a complete response letter and concerns about manufacturing.

Kevzara is indicated for adult patients with moderate to severe, active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to at least one DMARD. It is and anti-IL-6 receptor targeted therapy.

Sarilumab is off to a unique start with the manufacturers pricing the product 30% lower than TNF inhibitor competitors, and will carry a list price of $39,000 per year for the 200 milligram and 150 mg doses.

FDA approval is based on approximately 2,900 RA patients where it has been shown to yield significant clinical improvement and significantly less radiographic progression compared to placebo plus MTX.

The safety profile of sarilumab appears to be similar to other IL-6 inhibitors studied in RA.

The package insert (http://buff.ly/2rPpTFc) states that the drug is indicated for use as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs, at a dose of 200 mg once given subcutaneously every two weeks,  It comes with warnings about serious infection, bowel perforations, neutropenia, transaminitis and hyperlipidemia. It requires TB screening prior to use and should not be given with live virus vaccines. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Increased Deaths in RA, Despite Decreasing Mortality Rates

Data from the Swedish Rheumatology Quality (SRQ) Register studied death rates in patients with rheumatoid arthritis (RA) between 1997 and 2014.  Holmqvist and colleagues studied 17,512 RA and 78,847 matched controls from the general population, until their death.

For both the RA patients and general population, they noted steady decrease in mortality rates over time.

Mortality with Interstitial Lung Disease in Rheumatoid Arthritis

Annals of Rheumatic Disease has published a Danish population based study demonstrating the high mortality rates seen with interstitial lung disease (ILD).

Between the years 2004 and 2016, researchers identified 679 RA patients with RA-ILD and matched these (age, gender) against 11 722 RA patients without ILD.

Sarcoid and Rheumatoid Arthritis Risk Increased by Silica Exposure

A Swedish study has shown that occupational silica exposure increases the incidence rates of sarcoidosis and rheumatoid arthritis (RA) in those exposed workers in Swedish iron foundries.

Researchers studied personnel records from 10 iron foundries to identify workers who may be at risk.  They examined 2187 silica-exposed male workers exposed for at least 1 year for a total of 23,807 person-years at risk.

Rheumatoid Arthritis Augments Cardiovascular Risk

A large multi-center study of cardiovascular (CV) risk factors in rheumatoid arthritis (RA) has shown, after nearly 6 years follow-up, more CV events in males than females (21% vs. 11%, respectively) and that RA itself accounts for 30% of the attributable CV risk.

Do Rheumatologists Use ACR/EULAR Guidance on Rheumatoid Arthritis? “Live Vote” Results

The June 2017 RheumNow “Live Vote” surveyed US and non-US rheumatologists and patients about how they diagnose and treat rheumatoid arthritis (RA) and whether they rely on newer diagnostic criteria and management guidelines propagated by the American College of Rheumatology (ACR).